

**Table 10.1 Selected Kinase Inhibitors in the Market or That Have Entered Clinical Development—cont'd**

Type	Target	Agents
Ser–Thr kinases	JAK–STAT and PRL	Small-molecule inhibitors Ruxolitinib (INCB018424, Jakafi <sup>®</sup> ) FLLL-32 Monoclonal antibody LFA102
	BTK	Small-molecule inhibitor Ibrutinib (PCI-32765, Imbruvica <sup>®</sup> )
	Trk	Small-molecule inhibitor LOXO-101
	CDK	Small-molecule inhibitors Alvocidib (flavopiridol, HMR-1275) Rivaciclib (P776-00) Seleaciclib (roscovitine, CYC-202) SNS-032 (BMS-387032) AT7519 Indisulam (E-7070 <sup>®</sup> ) Palbociclib (PD-0332991, Ibrance <sup>®</sup> ) LEE011 Dinaciclib (SCH-727965) SB-1317 (TG-02) BAY-1000394 RGB-286638 Terameprocol (EM-1421) Milciclib (PHA-848125) AG-24332 ZK-304709 R-547 AZD-5438
	PLK1	Small-molecule inhibitors Volasertib
	PLK4	Small-molecule inhibitor CFI-400945
	CHKs	Small-molecule inhibitors UCN-01 LY 2603618 LY 2606368 PF-00477736 SCH900776 AZD-7762 XL-844 (EXEL-9844) GDC-0575 (ARRY-575) GDC-0425

*Continued*